Back to Search
Start Over
Complete loss of lineage defining antigens in two cases of B-cell malignancies following CAR-T therapy.
- Source :
-
Journal of hematopathology [J Hematop] 2024 Aug 26. Date of Electronic Publication: 2024 Aug 26. - Publication Year :
- 2024
- Publisher :
- Ahead of Print
-
Abstract
- Targeted immunotherapy is a promising approach in treating high-risk and refractory/relapsed lymphoid malignancies. Although this strategy has shown a significant success in treating non-Hodgkin B-cell lymphomas and plasma cell myeloma, relapse with loss of targeted antigen can occur. Rarely, complete loss of multiple lineage specific markers can happen. We are describing 2 cases of B-cell neoplasms along with contributing immunohistochemistry, cytogenetic, and molecular results. Post-targeted CAR-T therapy, both cases, one aggressive B-cell lymphoma and the other plasma cell myeloma, lost B-cell, and plasma cell antigens, respectively. Complete loss of lineage specific markers post-targeted therapy is a rare event that makes the diagnosis of the relapsed neoplasm challenging. In this article, we also reviewed the literature and highlighted possible mechanisms of antigen loss following targeted therapy.<br /> (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Details
- Language :
- English
- ISSN :
- 1865-5785
- Database :
- MEDLINE
- Journal :
- Journal of hematopathology
- Publication Type :
- Academic Journal
- Accession number :
- 39186243
- Full Text :
- https://doi.org/10.1007/s12308-024-00602-w